References
- Zhai XW, Cheng FWT, Lee V, Leung WK, Ng MHL, Tsang KS, et al. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. Pediatr Hematol Oncol. 2011; 28:269–78.
- Vedi A, Mitchell R, Shanmuganathan S, Oswald C, Marshall GM, Trahair T, et al. Increased survival for children with acute myeloid leukemia results from improved postrelapse treatment. J Pediatr Hematol Oncol. 2018; 40:541–7.
- Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012; 120:3187–205.
- Kairiene I, Pasauliene R, Lipunova N, Vaitkeviciene G, Rageliene L, Rascon J. Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience. Eur J Pediatr. 2017; 176:1329–37.
- Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012; 119:5980–8.
- Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2018; 18:277–93.
- Lins MM, Mello MJG, Ribeiro RC, De Camargo B, de Fátima Pessoa Militão, de Albuquerque M, Thuler LCS. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country. Ann Hematol. 2019; 98:1403–11.
- Xing S, Wang B, Gao Y, Li M, Wang T, Sun Y, et al. Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. Int J Lab Hematol. 2019; 41:485–92.
- Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, et al. Multiplex fusion gene testing in pediatric acute myeloid leukemia. Pediatr Int. 2018; 60:47–51.
- Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017; 129:3051–8.
- McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019; 33:1934–43.
- Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013; 122:170–8.
- Subspecialty Group of Hematology Diseases; Society of Pediatrics; Chinese Medical Association; Editorial Board of Chinese Journal of Pediatrics, Lungjun G, et al. [Recommendations for diagnosis and treatment of acute myelocytic leukemia in children]. Zhonghua Er Ke Za Zhi. [Chin J Pediatr]. 2006; 44:877–8. [in Chinese]
- Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Br J Cancer. 2015; 112:251–9.
- O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15:926–57.
- Jastaniah W, Bayoumy M, Alsultan A, Al Daama S, Ballourah W, Al-Anzi F, et al. Identifying prognostic factors that influence outcome of childhood acute myeloid leukemia in first relapse in Saudi Arabia: results of the multicenter SAPHOS Study. Clin Lymphoma Myeloma Leuk. 2018; 18:773–80.
- Ruan M, Wang Y-Q, Zhang L, Zou Y, Zhu X-F. [Analyses of karyotypic characteristics and prognosis in pediatric acute myeloblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. [Chin J Hematol]. 2012; 33:725–8. [in Chinese, English abstract].
- Sandahl JD, Kjeldsen E, Abrahamsson J, Ha SY, Heldrup J, Jahnukainen K, et al. Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study. Genes Chromosomes Cancer. 2014; 53:667–75.
- So C-C, Wan TS, Chow JL, Hui K-C, Choi WW, Lam CC, Chan L-C. A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia—evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients. Cancer Genet. 2011; 204:430–8.
- Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014; 28:1449–58.
- Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DKH, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010; 28:2674–81.
- Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005; 106:447–453.
- Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol. 2007; 78:468–76.
- Kömür M, Erbey F, Bayram I, Tanyeli A. Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. Asian Pac J Cancer Prev. 2010; 11:1393–5.
- Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology Am Soc Hematol Educ Program. 2017; 2017:37–44.
- Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, et al. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi [Chin J Hematol]. 2018; 39:9–14. [in Chinese, English abstract]
- He J, Xue Y, He H, Li J, Song X, Huang Y, et al. [Clinical and biological characteristics in childhood acute myeloid leukemia with 8;21 translocation]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi [Chin J Med Genetics]. 2004; 21:512–4. [in Chinese, English abstract].
- Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018; 59:2273–86.
- Wang CL, Ding BJ, Jiang L, Yin CX, Zhong QX, Yu GP, et al. Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat. Neoplasma. 2015; 62:864–71.
- Kim M, Kim J, Kim JR, Han E, Park J, Lim J, et al. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1. Mol Biol Rep. 2015; 42:451–6.
- Ding C, Chen S-N, Macleod RAF, Drexler HG, Nagel S, Wu D-P, et al. MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. Ups J Med Sci. 2018; 123:19–27.
- Debaize L, Jakobczyk H, Avner S, Gaudichon J, Rio A-G, Sérandour AA, et al. Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. Nucleic Acids Res. 2018; 46:11214–228.
- Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, et al. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Ann Hematol. 2019; 98:83–91.